View Cart (0 items)

Pharmaceutical

Dietary supplement maker withdraws products over manufacturing practice violations

A dietary supplement manufacturer has been ordered to stop selling its products after failing to follow manufacturing practice regulations.
Read More

Crop growth affected by drugs in the environment

Residues of commonly used drugs in the environment are likely to have a significant impact on plant growth, a new study suggests.
Read More

Shire agrees to acquire NPS Pharma for $5.2 billion

British pharmaceutical company Shire plc has agreed to acquire U.S.-based NPS Pharma for $5.2 billion, strengthening its capabilities in treating rare diseases and gastrointestinal disorders.
Read More

Pfizer boosts vaccine portfolio with Redvax acquisition

Pfizer Inc. has acquired a controlling interest in Switzerland's Redvax GmbH, the company announced on Monday.
Read More

Innovation helps bioadhesives meet unmet needs

Bioadhesives -- natural substances that act as adhesives -- have applications in key industries, and product innovation in this field is addressing unmet needs.
Read More

Avid Bioservices expands contract manufacturing capacity

Avid Bioservices, Inc. is to more than double its manufacturing capacity with a new production facility adjacent to its current campus in Tustin, California.
Read More

Pharmaceutical excipients market worth $6.1 billion this year

The market for pharmaceutical excipients has seen strong growth over the past few years and is forecast to expand at a compound annual growth rate (CAGR) of 6.7 percent from 2014 to 2019.
Read More

BioMarin to acquire DMD drug developer Prosensa

Biopharmaceuticals company BioMarin Pharmaceutical Inc. revealed on Monday that it has agreed to acquire Prosensa Holding N.V., a drug developer with a focus on rare neuromuscular and neurodegenerative disorders.
Read More

Merck agrees to $8.4 billion deal for antibiotics developer Cubist

Healthcare giant Merck & Co., Inc. is to acquire antibiotics specialist Cubist Pharmaceuticals, Inc. for $8.4 billion, the company announced on Monday.
Read More

Rise in asthma, COPD cases driving pulmonary drug delivery systems market

The global market revenue of pulmonary drug delivery systems is expected to increase at a compound annual growth rate (CAGR) of 8.9 percent over the period 2014-2019.
Read More